Jazz Pharmaceuticals (JAZZ) stock took off on Monday after the biopharmaceutical company announced results from a Phase 3 clinical trial. This clinical trial focused on using Ziihera combined with chemotherapy or PD-1 inhibitor Tevimbra as a treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma, including cancers of the stomach, gastroesophageal junction, and esophagus.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The exciting news that Jazz Pharmaceuticals investors need to consider are the results of this trial. Ziihera was effective when combined with chemotherapy or PD-1 inhibitor Tevimbra during the study. It showed statistically significant and clinically meaningful improvements in progression-free survival when compared to the control arm, which was trastuzumab plus chemotherapy. Additionally, overall survival rates were also increased in patients who received Ziihera plus tislelizumab and chemotherapy.
Rob Iannone, Executive Vice President, Global Head of Research and Development, and Chief Medical Officer of Jazz Pharmaceuticals, said, “We plan to quickly engage FDA and expect to submit a supplemental Biologics License Application (sBLA) in the U.S. in first half of 2026 to support Ziihera as a first-line treatment for patients with HER2+ locally advanced or metastatic GEA for use as part of a standard chemotherapy regimen with and without tislelizumab.”
Jazz Pharmaceuticals Stock Movement Today
Jazz Pharmaceuticals stock was up 20.51% on Monday, extending a 37.23% rally year-to-date. The stock has also increased 19.97% over the past 12 months.
Today’s news came with heavy trading of Jazz Pharmaceuticals stock, as more than 1.35 million shares have changed hands as of this writing. To put that in perspective, the company’s three-month daily average trading volume is about 713,000 units.
Is Jazz Pharmaceuticals Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for Jazz Pharmaceuticals is Strong Buy, based on 12 Buy ratings over the past three months. With that comes an average JAZZ stock price target of $194, representing a potential 13.7% upside for the shares.
